•Primary angiosarcoma of the ovary historically has no standard treatment due to its rarity, and outcomes have been variable.•Olaparib may represent a viable treatment option for primary angiosarcoma of the ovary with a somatic BRCA mutation.•Next-generation sequencing may play an important component in treatment of very rare cancers to guide new or uncommon therapies.
Keywords: Angiosarcoma; Next-generation sequencing; Olaparib; Ovarian cancer; Primary cytoreductive surgery.
© 2023 The Authors. Published by Elsevier Inc.